| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2008;39:384.)
© 2008 American Heart Association, Inc.
Original Contributions |
From the Department of Neurology (A.B.), Division of Pediatric Endocrinology (R.R.S.), and Division of Biostatistics (C.S.), Indiana University School of Medicine, and the Roudebush Veterans Affairs Medical Center (L.S.W.), Indianapolis, Ind; the Department of Neurology (T.A.K.), Baylor College of Medicine, Houston, Tex; the Department of Neurology (B.M.C.), University of Arizona School of Medicine, Tucson, Ariz; the Department of Neurology (K.J.B.), University of Washington School of Medicine, Seattle, Wash; and the Department of Neurology (B.M.K.), University of Cincinnati School of Medicine, Cincinnati, Ohio.
Correspondence to Askiel Bruno, MD, Department of Neurology, Indiana University School of Medicine, 1050 Wishard Blvd, 6th Floor, Indianapolis, IN 46202. E-mail abruno{at}iupui.edu
Background and Purpose— Hyperglycemia may worsen brain injury during acute cerebral infarction. We tested the feasibility and tolerability of aggressive hyperglycemia correction with intravenous insulin compared with usual care during acute cerebral infarction.
Methods— We conducted a randomized, multicenter, blinded pilot trial for patients with cerebral infarction within 12 hours after onset, a baseline glucose value
8.3 mmol/L (
150 mg/dL), and a National Institutes of Health Stroke Scale score of 3 to 22. Patients were randomized 2:1 to aggressive treatment with continuous intravenous insulin or subcutaneous insulin QID as needed (usual care). Target glucose levels were <7.2 mmol/L (<130 mg/dL) in the aggressive-treatment group and <11.1 mmol/L (<200 mg/dL) in the usual-care group. Glucose was monitored every 1 to 2 hours, and the protocol treatments continued for up to 72 hours. Final clinical outcomes were assessed at 3 months.
Results— We randomized 46 patients (31 to aggressive treatment and 15 to usual care). All patients in the aggressive-treatment group and 11 (73%) in the usual-care group had diabetes (P=0.008). Glucose levels were significantly lower in the aggressive-treatment group throughout protocol treatment (7.4 vs 10.5 mmol/L [133 vs 190 mg/dL], P<0.001). Hypoglycemia <3.3 mmol/L (<60 mg/dL) occurred only in the aggressive-treatment group (11 patients, 35%), 4 (13%) of whom had brief symptoms, including only 1 (3%) neurologic. Final clinical outcomes were nonsignificantly better in the aggressive-treatment group.
Conclusions— The intravenous insulin protocol corrected hyperglycemia during acute cerebral infarction significantly better than usual care without major adverse events and should be investigated in a clinical efficacy trial.
Key Words: brain infarction diabetes mellitus hyperglycemia insulin
This article has been cited by other articles:
![]() |
J. E. O'Connell, A. J. Hildreth, and C. S. Gray The Glycemia in Acute Stroke Study Stroke, July 1, 2009; 40(7): e511 - e511. [Full Text] [PDF] |
||||
![]() |
B. Fuentes, J. Castillo, E. Cobo, and E. Diez-Tejedor Response to Letter by O'Connell et al Stroke, July 1, 2009; 40(7): e512 - e513. [Full Text] [PDF] |
||||
![]() |
N. D. Kruyt, G. J. Biessels, R. J. de Haan, M. Vermeulen, G. J.E. Rinkel, B. Coert, and Y. B.W.E.M. Roos Hyperglycemia and Clinical Outcome in Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis Stroke, June 1, 2009; 40(6): e424 - e430. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Higgins and K. R. Lees Advances in Emerging Therapies Stroke, May 1, 2009; 40(5): e292 - e294. [Full Text] [PDF] |
||||
![]() |
D. E.G. Griesdale, R. J. de Souza, R. M. van Dam, D. K. Heyland, D. J. Cook, A. Malhotra, R. Dhaliwal, W. R. Henderson, D. R. Chittock, S. Finfer, et al. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data Can. Med. Assoc. J., April 14, 2009; 180(8): 821 - 827. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Y. Poppe, S. R. Majumdar, T. Jeerakathil, W. Ghali, A. M. Buchan, M. D. Hill, and the Canadian Alteplase for Stroke Effectiveness St Admission Hyperglycemia Predicts a Worse Outcome in Stroke Patients Treated With Intravenous Thrombolysis Diabetes Care, April 1, 2009; 32(4): 617 - 622. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Fuentes, J. Castillo, B. San Jose, R. Leira, J. Serena, J. Vivancos, A. Davalos, A. G. Nunez, J. Egido, E. Diez-Tejedor, et al. The Prognostic Value of Capillary Glucose Levels in Acute Stroke: The GLycemia in Acute Stroke (GLIAS) Study Stroke, February 1, 2009; 40(2): 562 - 568. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Collino, M. Aragno, S. Castiglia, C. Tomasinelli, C. Thiemermann, G. Boccuzzi, and R. Fantozzi Insulin Reduces Cerebral Ischemia/Reperfusion Injury in the Hippocampus of Diabetic Rats: A Role for Glycogen Synthase Kinase-3{beta} Diabetes, January 1, 2009; 58(1): 235 - 242. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Wiener, D. C. Wiener, and R. J. Larson Benefits and Risks of Tight Glucose Control in Critically Ill Adults: A Meta-analysis JAMA, August 27, 2008; 300(8): 933 - 944. [Abstract] [Full Text] [PDF] |
||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2008 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |